{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:19:49Z","timestamp":1770797989060,"version":"3.50.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.vaccine.2016.07.051","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T17:04:05Z","timestamp":1471021445000},"page":"4724-4731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine"],"prefix":"10.1016","volume":"34","author":[{"given":"Gaurav","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Giannino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayan","family":"Rishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Glueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2016.07.051_b0005","first-page":"15","article-title":"Epidemiology of cancers of infectious origin and prevention strategies","volume":"56","author":"De Flora","year":"2015","journal-title":"J Prev Med Hyg"},{"issue":"11","key":"10.1016\/j.vaccine.2016.07.051_b0010","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"De Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.07.051_b0015","first-page":"166","article-title":"General aspects of structure, classification and replication of human papillomavirus","volume":"53","author":"Santos-L\u00f3pez","year":"2015","journal-title":"Rev Med Inst Mex Seguro"},{"issue":"24","key":"10.1016\/j.vaccine.2016.07.051_b0020","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2016.07.051_b0025","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1128\/JVI.70.9.5875-5883.1996","article-title":"In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype","volume":"70","author":"Roden","year":"1996","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2016.07.051_b0030","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345 years: end-of-study analysis of a Phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2016.07.051_b0035","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/cncr.29374","article-title":"FDA approves Gardasil 9 for more types of HPV","volume":"121","author":"Printz","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2016.07.051_b0040","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, Phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil\u00ae in 9\u201315-year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2016.07.051_b0045","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2016.07.051_b0050","first-page":"1401","article-title":"Measles virus","volume":"vol. 2","author":"Griffin","year":"2001"},{"issue":"4","key":"10.1016\/j.vaccine.2016.07.051_b0055","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/v8040109","article-title":"Constraints on the genetic and antigenic variability of measles virus","volume":"8","author":"Beaty","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.07.051_b0060","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","article-title":"Rescue of measles viruses from cloned DNA","volume":"14","author":"Radecke","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2016.07.051_b0065","first-page":"129","article-title":"Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses","volume":"329","author":"Billeter","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.07.051_b0070","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","article-title":"A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice","volume":"73","author":"Singh","year":"1999","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.07.051_b0075","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/vim.2005.18.317","article-title":"Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector","volume":"18","author":"Tangy","year":"2005","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2016.07.051_b0080","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1099\/0022-1317-80-1-101","article-title":"A recombinant measles virus expressing biologically active human interleukin-12","volume":"80","author":"Singh","year":"1999","journal-title":"J Gen Virol"},{"issue":"26","key":"10.1016\/j.vaccine.2016.07.051_b0085","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1016\/j.vaccine.2009.01.057","article-title":"Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses","volume":"27","author":"Liniger","year":"2009","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2016.07.051_b0090","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.1016\/j.vaccine.2013.09.072","article-title":"Immunogenicity of a recombinant measles HIV-1 subtype C vaccine","volume":"31","author":"Stebbings","year":"2013","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2016.07.051_b0095","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3390\/v5102384","article-title":"Vaccines in development against West Nile virus","volume":"5","author":"Brandler","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.07.051_b0100","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.virol.2014.01.002","article-title":"Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein","volume":"453","author":"Escriou","year":"2014","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2016.07.051_b0105","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2016.07.051_b0110","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.07.051_b0115","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1128\/JVI.78.1.146-157.2004","article-title":"A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV","volume":"78","author":"Lorin","year":"2004","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.07.051_b0120","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1371\/journal.pntd.0000096","article-title":"Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus","volume":"1","author":"Brandler","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"issue":"26","key":"10.1016\/j.vaccine.2016.07.051_b0125","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1016\/j.vaccine.2009.01.061","article-title":"Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma","volume":"27","author":"Cantarella","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.07.051_b0130","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","article-title":"Measles virus spread and pathogenesis in genetically modified mice","volume":"72","author":"Mrkic","year":"1998","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2016.07.051_b0135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00705-009-0484-8","article-title":"Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris","volume":"154","author":"Bazan","year":"2009","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2016.07.051_b9000","series-title":"Molecular Cloning: A Laboratory Manual","article-title":"Directional cloning","volume":"vol. 1","author":"Sambrook","year":"2001"},{"issue":"5","key":"10.1016\/j.vaccine.2016.07.051_b0140","first-page":"1","article-title":"Monte Carlo simulation of the Spearman-Kaerber TCID50","volume":"2","author":"Wulff","year":"2012","journal-title":"J Clin Bioinformat"},{"issue":"2","key":"10.1016\/j.vaccine.2016.07.051_b0145","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.virol.2003.12.027","article-title":"Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18","volume":"321","author":"Pastrana","year":"2004","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.vaccine.2016.07.051_b0150","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1128\/JVI.79.5.2839-2846.2005","article-title":"Maturation of papillomavirus capsids","volume":"79","author":"Buck","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2016.07.051_b0155","first-page":"107","article-title":"Cervarix\u2122: a vaccine for the prevention of HPV 16, 18-associated cervical cancer","volume":"2","author":"Monie","year":"2008","journal-title":"Biologics"},{"issue":"7","key":"10.1016\/j.vaccine.2016.07.051_b0160","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1128\/CVI.00139-12","article-title":"A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies","volume":"19","author":"Day","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"30","key":"10.1016\/j.vaccine.2016.07.051_b0165","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1016\/j.vaccine.2008.04.074","article-title":"Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women","volume":"26","author":"Kemp","year":"2008","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2016.07.051_b0170","doi-asserted-by":"publisher","first-page":"9805","DOI":"10.1128\/JVI.01336-08","article-title":"What are the risks\u2014hypothetical and observed\u2014of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses?","volume":"82","author":"Peter","year":"2008","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16306491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16306491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T04:21:42Z","timestamp":1601007702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16306491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":35,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0264410X16306491"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.07.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.07.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}